Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Target Population
2.2. Follow-Up and Measurements
2.3. Liver Stiffness Measurement
2.4. Study Outcomes
- -
- New onset of: (1) ascites; (2) variceal bleeding; (3) spontaneous bacterial peritonitis; (4) hepatic encephalopathy; (5) liver transplantation: (6) death for Child–Pugh A and B patients;
- -
- Occurrence of de novo HCC;
- -
- In Child–Pugh B patients, worsening of a pre-existing symptom of decompensated cirrhosis (i.e., need for an increased dose of diuretics, addition of rifaximin for hepatic encephalopathy, or hospital admission for a new liver failure event) were also considered as LRE.
2.5. Statistical Analysis
3. Results
3.1. Patients’ Characteristics
3.2. Incidence of Liver-Related Events
3.3. Basal Predictors of Liver-Related Events
3.4. Dynamics of Liver Stiffness Measurements
4. Discussion
- SVR patients at the highest likelihood of lack of LRE are females and those with basal LSM < 20 kPa who have a 10-fold lower incidence of LRE at 5 years after SVR as compared to males and those with a basal LSM ≥ 20 kPa.
- The magnitude of fibrosis regression in SVR patients without LRE at 5 years depends on the basal LSM; results are higher in patients with more severe liver fibrosis at baseline. The reduction of LSM, at 5 years after SVR, is between 18.08% and 37.2%.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Carrat, F.; Fontaine, H.; Dorival, C.; Simony, M.; Diallo, A.; Hezode, C.; De Ledinghen, V.; Larrey, D.; Haour, G.; Bronowicki, J.-P.; et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study. Lancet 2019, 393, 1453–1464. [Google Scholar] [CrossRef] [PubMed]
- Nahon, P.; Bourcier, V.; Layese, R.; Audureau, E.; Cagnot, C.; Marcellin, P.; Guyader, D.; Fontaine, H.; Larrey, D.; De Lédinghen, V.; et al. Eradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 2017, 152, 142–156.e2. [Google Scholar] [CrossRef] [PubMed]
- Foster, G.R.; Irving, W.L.; Cheung, M.C.; Walker, A.J.; Hudson, B.E.; Verma, S.; McLauchlan, J.; Mutimer, D.J.; Brown, A.; Gelson, W.T.; et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 2016, 64, 1224–1231. [Google Scholar] [CrossRef]
- D’ambrosio, R.; Degasperi, E.; Anolli, M.P.; Fanetti, I.; Borghi, M.; Soffredini, R.; Iavarone, M.; Tosetti, G.; Perbellini, R.; Sangiovanni, A.; et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J. Hepatol. 2022, 76, 302–310. [Google Scholar] [CrossRef]
- Fernández-Alvarez, P.; Guerra-Veloz, M.F.; Vilches-Arenas, A.; Cordero-Ruíz, P.; Bellido-Muñoz, F.; Caunedo-Alvarez, A.; Carmona-Soria, I. Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients. Viruses 2023, 15, 1251. [Google Scholar] [CrossRef]
- Kondili, L.A.; Quaranta, M.G.; Cavalletto, L.; Calvaruso, V.; Ferrigno, L.; D’Ambrosio, R.; Simonelli, I.; Brancaccio, G.; Raimondo, G.; Brunetto, M.R.; et al. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. Dig. Liver Dis. 2023, 55, 907–917. [Google Scholar] [CrossRef]
- Morisco, F.; Federico, A.; Marignani, M.; Cannavò, M.; Pontillo, G.; Guarino, M.; Dallio, M.; Begini, P.; Benigno, R.G.; Lombardo, F.L.; et al. Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. Cancers 2021, 13, 3810. [Google Scholar] [CrossRef] [PubMed]
- Lens, S.; Alvarado-Tapias, E.; Mariño, Z.; Londoño, M.-C.; Llop, E.; Martinez, J.; Fortea, J.I.; Ibañez, L.; Ariza, X.; Baiges, A.; et al. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-Associated Cirrhosis. Gastroenterology 2017, 153, 1273–1283.e1. [Google Scholar] [CrossRef]
- Semmler, G.; Lens, S.; Meyer, E.L.; Baiges, A.; Alvarado-Tapias, E.; Llop, E.; Tellez, L.; Schwabl, P.; Mauro, E.; Escudé, L.; et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J. Hepatol. 2022, 77, 1573–1585. [Google Scholar] [CrossRef]
- Rockey, D.C.; Friedman, S.L. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology 2021, 160, 1502–1520.e1. [Google Scholar] [CrossRef]
- Available online: https://aifa.gov.it/aggiornamento-epatite-c (accessed on 16 October 2019).
- The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20, 15–20. [Google Scholar] [CrossRef]
- Fraquelli, M.; Rigamonti, C.; Casazza, G.; Conte, D.; Donato, M.F.; Ronchi, G.; Colombo, M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56, 968–973. [Google Scholar] [CrossRef] [PubMed]
- Gaiani, S.; Gramantieri, L.; Venturoli, N.; Piscaglia, F.; Siringo, S.; D’Errico, A.; Zironi, G.; Grigioni, W.; Bolondi, L. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J. Hepatol. 1997, 27, 979–985. [Google Scholar] [CrossRef] [PubMed]
- European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015, 63, 199–236. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://www.webaisf.org/wp-content/uploads/2020/12/DOCUMENTO-HCV-14_12_20.pdf (accessed on 14 December 2020).
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar] [CrossRef]
- Boursier, J.; Decraecker, M.; Bourlière, M.; Bureau, C.; Ganne-Carrié, N.; de Lédinghen, V. Quality criteria for the measurement of liver stiffness. Clin. Res. Hepatol. Gastroenterol. 2021, 46, 101761. [Google Scholar] [CrossRef]
- Pons, M.; Rodríguez-Tajes, S.; Esteban, J.I.; Mariño, Z.; Vargas, V.; Lens, S.; Buti, M.; Augustin, S.; Forns, X.; Mínguez, B.; et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J. Hepatol. 2020, 72, 472–480. [Google Scholar] [CrossRef]
- Calvaruso, V.; Cabibbo, G.; Cacciola, I.; Petta, S.; Madonia, S.; Bellia, A.; Tinè, F.; Distefano, M.; Licata, A.; Giannitrapani, L.; et al. Incidence of Hepatocellular Carcinoma in Patients with HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology 2018, 155, 411–421.e4. [Google Scholar] [CrossRef] [PubMed]
- Vutien, P.; Kim, N.J.; Moon, A.M.; Johnson, K.M.; Berry, K.; Green, P.K.; Ioannou, G.N. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Aliment. Pharmacol. Ther. 2024, 59, 361–371. [Google Scholar] [CrossRef]
- Nicoletti, A.; Ainora, M.E.; Cintoni, M.; Garcovich, M.; Funaro, B.; Pecere, S.; De Siena, M.; Santopaolo, F.; Ponziani, F.R.; Riccardi, L.; et al. Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals. Dig. Liver Dis. 2023, 55, 1472–1479. [Google Scholar] [CrossRef]
- de Franchis, R.; Bosch, J.; Garcia-Tsao, G.; Reiberger, T.; Ripoll, C.; Baveno VII Faculty. Baveno VII—Renewing consensus in portal hypertension. J. Hepatol. 2022, 76, 959–974. [Google Scholar] [CrossRef] [PubMed]
- Semmler, G.; Yang, Z.; Fritz, L.; Köck, F.; Hofer, B.S.; Balcar, L.; Hartl, L.; Jachs, M.; Stopfer, K.; Schedlbauer, A.; et al. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease. Gastroenterology 2023, 165, 1041–1052. [Google Scholar] [CrossRef] [PubMed]
- Kanwal, F.; Kramer, J.R.; Asch, S.M.; Cao, Y.; Li, L.; El-Serag, H.B. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated with Direct Acting Antiviral Agents. Hepatology 2020, 71, 44–55. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Facciorusso, A.; Loomba, R.; Falck-Ytter, Y.T. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients with Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2018, 16, 27–38.e4. [Google Scholar] [CrossRef]
- Knop, V.; Hoppe, D.; Vermehren, J.; Troetschler, S.; Herrmann, E.; Vermehren, A.; Friedrich-Rust, M.; Sarrazin, C.; Trebicka, J.; Zeuzem, S.; et al. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study. J. Viral Hepat. 2021, 28, 1604–1613. [Google Scholar] [CrossRef]
- Piecha, F.; Gänßler, J.-M.; Ozga, A.-K.; Wehmeyer, M.H.; Kluwe, J.; Lampalzer, S.; Creutzfeldt, A.M.; Buescher, G.; Horvatits, T.; Sterneck, M.; et al. Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. Scand. J. Gastroenterol. 2021, 56, 840–848. [Google Scholar] [CrossRef]
- Kang, Q.; Xu, J.; Luo, H.; Tan, N.; Chen, H.; Cheng, R.; Pan, J.; Han, Y.; Yang, Y.; Liu, D.; et al. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J. Viral Hep. 2021, 28, 1284–1292. [Google Scholar] [CrossRef]
Characteristics | n (%) | |
---|---|---|
575 | ||
Sex | Male | 305 (53.0) |
Female | 270 (47.0) | |
Sex ratio | M/F | 1.1 |
Age, years | ≤50 | 83 (14.4) |
51–65 | 196 (34.1) | |
>65 | 296 (51.5) | |
Mean age ± SD | 64.1 ± 12.0 | |
Previous IFN treatment | ||
Yes | 296 (51.5) | |
No | 279 (48.5) | |
Child–Pugh * | ||
A | 543 (94.4) | |
B | 32 (5.6) | |
LSM (kPa) ** | <20 | 390 (71.3) |
≥20 | 157 (28.7) | |
Mean LSM ± SD § | 19.2 ± 7.6 | |
Genotype | 1 | 459 (79.8) |
other | 116 (20.2) | |
DAAs Therapy | SOF | 45 (7.8) |
SOF + other | 373 (72.7) | |
3D | 132 (23.0) | |
2D | 9 (1.6) | |
other | 16 (2.8) | |
Ribavirin | Yes | 222 (38.6) |
No | 353 (61.4) |
Events | n | Incidence Rate per 100 p/y (95% CI) |
---|---|---|
Overall death | 51 | 1.9 (1.4–2.5) |
Death for hepatic causes | 17 | 0.6 (0.4–1.0) |
Death for non-hepatic causes | 34 | 1.3 (0.9–1.8) |
Any liver decompensation * | 43 | 1.6 (1.2–2.2) |
HCC # | 41 | 1.6 (1.2–2.2) |
Liver transplantation | 3 | 0.1 (0.0–0.3) |
Any event § | 98 | 3.9 (3.2–4.7) |
Liver Decompensation | HCC | ||||||||
---|---|---|---|---|---|---|---|---|---|
Characteristics | HRcrude (95% IC) | p | HRadj (95% IC) | p | HRcrude (95% IC) | p | HRadj (95% IC) | p | |
Sex | F | 1 | 1 | ||||||
M | 1.0 (0.5–1.8) | 0.969 | 2.5 (1.3–5.1) | 0.008 | 3.6 (1.6–8.0) | 0.002 | |||
Age (y) | <65 | 1 | 1 | 1 | |||||
≥65 | 2.8 (1.4–5.7) | 0.005 | 2.2 (1.0–4.9) | 0.053 | 2.2 (1.1–4.2) | 0.026 | 2.0 (1.0–4.2) | 0.060 | |
Child-Pugh | A | 1 | 1 | 1 | |||||
B | 4.7 (2.1–10.5) | <0.001 | 1.3 (0.4–4.4) | 0.635 | 2.6 (0.9–7.3) | 0.075 | 2.1 (0.7–6.1) | 0.169 | |
LSM (kPa) | <20 | 1 | 1 | 1 | |||||
≥20 | 14.8 (5.7–38.4) | <0.001 | 13.5 (5.2–35.3) | <0.001 | 10.7 (4.6–24.5) | <0.001 | 9.2 (4.0–21.3) | <0.001 | |
Genotype | 1 | 1 | 1 | ||||||
other | 0.8 (0.4–1.8) | 0.661 | 0.9 (0.4–2.1) | 0.831 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Morisco, F.; Federico, A.; Marignani, M.; Lombardo, F.L.; Cossiga, V.; Ranieri, L.; Romeo, M.; Cipullo, M.; Begini, P.; Zannella, A.; et al. Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study. Viruses 2024, 16, 1439. https://doi.org/10.3390/v16091439
Morisco F, Federico A, Marignani M, Lombardo FL, Cossiga V, Ranieri L, Romeo M, Cipullo M, Begini P, Zannella A, et al. Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study. Viruses. 2024; 16(9):1439. https://doi.org/10.3390/v16091439
Chicago/Turabian StyleMorisco, Filomena, Alessandro Federico, Massimo Marignani, Flavia L. Lombardo, Valentina Cossiga, Luisa Ranieri, Mario Romeo, Marina Cipullo, Paola Begini, Alessandra Zannella, and et al. 2024. "Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study" Viruses 16, no. 9: 1439. https://doi.org/10.3390/v16091439
APA StyleMorisco, F., Federico, A., Marignani, M., Lombardo, F. L., Cossiga, V., Ranieri, L., Romeo, M., Cipullo, M., Begini, P., Zannella, A., & Stroffolini, T. (2024). Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study. Viruses, 16(9), 1439. https://doi.org/10.3390/v16091439